Level Bio AB (publ) (NGM:LEVBIO)

Market Cap	26.54M +28.9%
Revenue (ttm)	33.55M +22.4%
Net Income	-2.87M
EPS	n/a
Shares Out	68.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,542
Open	n/a
Previous Close	0.3360
Day's Range	n/a
52-Week Range	0.2640 - 0.4500
Beta	1.29
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Level Bio AB

Level Bio AB (publ) manufactures and distributes cutting-edge and diagnostic solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to Level Bio AB (publ) in May 2024. Level Bio AB (publ) was incorporated in 1998 and is headquartered in Stockholm, Sweden.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1998
• Employees: 10
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: LEVBIO

Financial Performance

In 2025, Level Bio AB's revenue was 32.36 million, an increase of 28.94% compared to the previous year's 25.10 million. Losses were -3.54 million, -55.04% less than in 2024.